Piper Sandler initiated coverage of Protara Therapeutics (TARA) with an Overweight rating and $24 price target The company is “under-the-radar” despite being a clinical stage biotech with three “potentially substantial and unique market opportunities,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002
- Protara gets FDA Breakthrough Therapy and Fast Track Designations for TARA-002
- Protara Therapeutics Raises $86.3 Million in Offering
- Protara Therapeutics Completes $75 Million Stock Offering
- Protara Therapeutics down 18% at $5.66 after equity offering